SIONNA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss
SIONNA THERAPEUTICS, INC. (SION) reported Debt Securities, Available-for-sale, Unrealized Loss of $459.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was $247.00K, a 850.00% increase year-over-year.
- SIONNA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $212.00K, a 1147.06% increase year-over-year.
- SIONNA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was -$15.00K.
- SIONNA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$22.00K.
- SIONNA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $1.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $459.00K 10-Q · filed 2026-08-06 | $444.00K derived: sum of 3 quarters · filed 2026-08-06 | $422.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $212.00K 10-Q · filed 2026-05-12 | $197.00K derived: sum of 2 quarters · filed 2026-08-06 | $175.00K derived: sum of 3 quarters · filed 2026-08-06 | $201.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$15.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | -$37.00K derived: sum of 2 quarters · filed 2026-08-06 | -$11.00K derived: sum of 3 quarters · filed 2026-08-06 | $6.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.00K derived: sum of 2 quarters · filed 2025-11-05 | $21.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $43.00K 10-Q · filed 2025-08-11 | ||
| 2025-03-31 | $17.00K 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $1.00K 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |